Читать книгу Pathy's Principles and Practice of Geriatric Medicine - Группа авторов - Страница 267

Reactivation of latent varicella zoster virus results in a localized eruption known as herpes zoster (shingles). Its incidence increases with age, occurring in up to half of individuals 85 or older. Postherpetic neuralgia is a potentially devastating complication, occurring in more than 40% of individuals older than 60.³³ In 2006, the FDA approved the use of Zostavax, which is only 30% protective. In 2016, the FDA approved Shingrix, which is 90% protective. The Advisory Committee on Immunization Practices (ACIP) recommends a one‐time dose of Shingrix to be given as a series of two injections to individuals 50 or older. Individuals who previously received Zostavax should receive Shingrix. All individuals 50 or older should receive varicella zoster vaccination regardless of a prior history of chicken pox.³³